CY-09

CY-09 is a NOD-like receptor protein 3 (NLRP3) inhibitor. It selectively inhibits NLRP3 ATPase activity over the ATPase activity of NLRP1, NLRC4, NOD2, and RIG-I at 1 µM. CY-09 binds directly to the ATP-binding motif of the NLRP3 NACHT domain (Kd = 500 nM) and suppresses NLRP3 inflammasome assembly. It inhibits NLRP3 inflammasome activation induced by nigericin (Cay-11437) in THP-1 cells when used at a concentration of 1 µM. CY-09 (5 mg/kg, i.p.) improves the left ventricle ejection fraction (LVEF) and left ventricle fractional shortening (LVFS) and reduces myocardial fibrosis in a mouse model of myocardial infarction induced by left anterior descending (LAD) coronary artery occlusion. It also reduces hepatic steatosis in a high-fat diet-induced mouse model of non-alcoholic fatty liver disease (NAFLD) when administered at a dose of 2.5 mg/kg.Formal Name: 4-[[4-oxo-2-thioxo-3-[[3-(trifluoromethyl)phenyl]methyl]-5-thiazolidinylidene]methyl]-benzoic acid. CAS Number: 1073612-91-5. Molecular Formula: C19H12F3NO3S2. Formula Weight: 423.4. Purity: >95%. Formulation: (Request formulation change), A crystalline solid. Solubility: DMF: 30 mg/ml, DMSO: 15 mg/ml. lambdamax: 277, 369, 384 nm. SMILES: OC(C1=CC=C(C=C2SC(N(CC3=CC=CC(C(F)(F)F)=C3)C2=O)=S)C=C1)=O. InChi Code: InChI=1S/C19H12F3NO3S2/c20-19(21,22)14-3-1-2-12(8-14)10-23-16(24)15(28-18(23)27)9-11-4-6-13(7-5-11)17(25)26/h1-9H,10H2,(H,25,26). InChi Key: DJTINRHPPGAPLD-UHFFFAOYSA-N.